⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
TLX News
Telix Pharmaceuticals Limited American Depositary Shares
Telix to Participate in Oppenheimer and TD Cowen Conferences
globenewswire.com
TLX
FY 2025 Results: Strong Commercial Growth, Focused Pipeline Investment
globenewswire.com
TLX
Telix Submits European Marketing Authorization Application for TLX101-Px for Brain Cancer Imaging
globenewswire.com
TLX
Co-PSMA: Cu-64 SAR-bisPSMA more than doubled prostate cancer lesion and patient detection vs. Ga-68 PSMA-11 in head-to-head trial
prnewswire.com
TLX
Telix Full Year Results 2025 Investor Webcast Notification
globenewswire.com
TLX
PSMA-Targeted Therapy Market Set to Expand by 2034 on Strong Pipeline and Increasing Diagnosis Rates | DelveInsight
prnewswire.com
LNTH
TLX
NVS
Telix Achieves FY 2025 Guidance with US$804M (A$1.2B) Revenue, Accelerates Growth with Gozellix Launch
globenewswire.com
TLX
First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study
globenewswire.com
TLX
Levi & Korsinsky Reminds Telix Pharmaceuticals Ltd. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 9, 2026 – TLX
globenewswire.com
TLX
TLX FINAL DEADLINE ALERT: Hagens Berman Alerts Telix Pharm. (TLX) Investors of Today’s Lead Plaintiff Deadline in Securities Class Action
globenewswire.com
TLX